Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
2015 · Health Technology Assessment · 832 citations
https://doi.org/10.3310/hta19140
E
Eldon Spackman
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
186
Papers
4.5K
Citations
31
h-index
71
i10-index
Eldon Spackman is an academic researcher from Twitter (United States). The author has contributed to research in topics: Health Systems, Economic Evaluations, Quality of Life & Pharmaceutical Economics and Policy & Spondyloarthritis Studies and Treatments. The author has an h-index of 31, co-authored 159 publications.
ORCID: 0000-0001-8558-5973Papers by this author
worksThe Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial
2013 · The Lancet · 233 citations
https://doi.org/10.1016/s0140-6736(12)61726-7
Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS)
2017 · European Urology · 173 citations
https://doi.org/10.1016/j.eururo.2017.08.018
Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis
2018 · Public health reviews · 147 citations
https://doi.org/10.1186/s40985-018-0093-8
First‐line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs
2021 · Diabetic Medicine · 20 citations
https://doi.org/10.1111/dme.14622
Trastuzumab for the treatment of HER2- positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2011 · Health Technology Assessment · 18 citations
https://doi.org/10.3310/hta15suppl1/04
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat